Clinical Trial

A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer

Withdrawn Phase 2
View on ClinicalTrials.gov →
Why the trial stopped
0 participants enrolled
Summary
This is a prospective single-center, single-arm, open-label, phase II study evaluating the safety, activity, and efficacy of regorafenib in combination with lorigerlimab for the treatment of patients with regrowing or locally recurrent pMMR/MSS localized rectal cancer following TNT.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-10-30; most recent amendment 2026-02-23.
Status change: Not Yet Recruiting → Withdrawn 2026-01-27
Trial Details
NCT Number NCT07223567
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Bayer, MacroGenics
Conditions Rectal Cancer, Rectal Cancer Recurrent
Start Date 2025-10-27
Primary Completion 2026-01-22 (estimated)
Study Completion 2026-01-22 (estimated)
Updated on ClinicalTrials.gov 2026-02-25